Creative Enzymes, a global enzyme technology service provider, has launched an AI-integrated platform designed to accelerate the development of biocatalysts for industrial biomanufacturing. The platform merges computational enzyme engineering with practical process development, offering solutions that are predictable in silico and stable at scale. Traditional enzyme development methods often fail to meet the speed required for iterative product development, but AI addresses this by predicting enzyme candidates, designing enzymes constrained by process parameters, and anticipating process performance using key molecular features.
The platform delivers AI-Driven Biocatalysis Solutions that reduce R&D costs by minimizing the need to test numerous biocatalyst variants. It also lowers the risk of process failure by identifying suitable enzymes earlier in development and enables access to molecules previously inaccessible to enzymatic conversion. This opens new product opportunities and allows for the development of novel biocatalytic processes.
Creative Enzymes offers three specialized service modules: AI-Driven Biocatalysis Solution (end-to-end discovery and engineering), AI-Driven Industrial Biocatalysis (scale-up and commercial production), and AI-Driven Green Biocatalysis (sustainability-focused solutions). The first module covers the entire value chain from target reaction analysis to scale-up characterization, reducing the design-build-test-learn cycle from 12–24 months to 8–12 months for moderately complex targets. The second module addresses substrate concentration optimization, cofactor regeneration, product inhibition management, immobilization, and process analytical technology integration. The third module focuses on environmental benefits, as enzymatic reactions typically occur in aqueous media at room temperature, minimizing organic solvent use and emissions.
In a recent case study, Creative Enzymes applied the platform to transaminase engineering using a 6D protein engineering framework that combined interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants, each with nine mutations, exhibited high solubility and catalytic stability at 7-liter fermentation scale. These engineered enzymes converted prochiral ketones to sitagliptin, achieving enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up production.
The platform's impact is most pronounced in pharmaceuticals, where asymmetric synthesis of chiral intermediates and replacement of hazardous reagents are already underway. Agrochemicals and food industries are also adopting AI biocatalysis to fine-tune toxicology profiles and deliver cleaner labels, respectively. Fine chemicals and personal care sectors are beginning to explore high-value conversions and more sustainable processes.
